Message from the President
AccuRna was founded in Japan in December 2015 as a collaborative venture between medical engineering and industry academia. It aims to promote innovative therapy in the form of Nucleic Acid Medicine utilizing “Nano DDS technology,” providing effective treatment for refractory diseases for which there is currently no cure.
Our dream is to deliver a “radical cure” to patients suffering from refractory diseases all over the world by safely and efficiently achieving the ultimate in molecular-targeted therapy.
Together with pharmaceutical companies, who are pioneers in innovative nucleic medicine, we aim to realize this dream of saving patients and providing a higher quality of life through innovative technology originating in Japan.